With unique ‘mechanism of action,’ drug could become first in new class of influenza antivirals
Development of an experimental influenza antiviral drug that may be more potent and could have a longer treatment window than existing drugs will receive support from the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR). The drug is being developed for use in treating patients hospitalized with influenza.
This post was imported from a legacy archive. Please excuse any formatting inconsistencies.